Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rollover protocol for patients continuing to benefit from ribociclib
2024-511125-61-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of ribociclib in cancer, sponsored by Novartis. Primary endpoint: Number of patients and duration of exposure to ribociclib under rollover study. Planned start Apr 2024; status: authorised.
02
Drugs
ribociclib
03
Conditions
cancer
Beyond the preview
Go deeper on 2024-511125-61-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511125-61-00.